The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Blue Faery Recognizes Excellence in Liver Cancer Research





$25,000 Grant Awarded to Support Innovative Hepatocellular Carcinoma Studies

LOS ANGELES, CA, April 08, 2025 /24-7PressRelease/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the Blue Faery Award (BFA) for Excellence in Liver Cancer Research recipient. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), remains the third leading cause of cancer-related deaths worldwide. Blue Faery established the award to honor medical professionals conducting groundbreaking research to improve patient outcomes.

The winner, Dr. Mark Yarchoan, said, "I am deeply honored to receive the Blue Faery Award, which not only supports liver cancer research but also highlights the strength of the community driving progress in this field."

Mark Yarchoan, M.D., is an Associate Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. He leads an NCI-funded laboratory focused on understanding and overcoming barriers to effective antitumor immunity. Dr. Yarchoan is at the forefront of advancing immunotherapy treatments for liver cancers and has served as Principal Investigator on several notable clinical trials, including the first clinical trials of a personalized neoantigen vaccine for HCC and neoadjuvant anti-PD1 immunotherapy in HCC. A recognized clinical expert in hepatobiliary cancers, he participates in international guideline committees for liver cancers for the American Association for the Study of Liver Diseases and the American Society of Clinical Oncology.

President Andrea Wilson Woods stated, "Recognizing and supporting innovative HCC research is crucial in the fight against this devastating disease. Liver cancer is one of the most common and deadliest cancers worldwide, and we are committed to advancing research that makes a real difference." Andrea founded Blue Faery in memory of her sister, Adrienne, who passed away from HCC at 15. The organization announces the annual award winner on Adrienne's birthday—this year, she would have turned 39.

Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy. Blue Faery hosts an online Liver Cancer Community for patients and caregivers. Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer. Blue Faery has three education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

AstraZeneca funded this year's award.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.